BDSI - BioDelivery Sciences International, Inc.
| Previous Close | 6.04 |
| Open | 6.04 |
| Bid | 5.75 x 2900 |
| Ask | 5.84 x 4000 |
| Day's Range | 5.81 - 6.19 |
| 52 Week Range | 3.59 - 7.21 |
| Volume | 816,724 |
| Avg. Volume | 1,523,564 |
| Market Cap | 574.723M |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.27 |
| Earnings Date | Mar 11, 2020 - Mar 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.43 |
- GlobeNewswire
BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic
2019 Total Company Net Sales Expected at Upper End of $105 to $110 Million More than 25 Million Additional Lives Moved to Preferred Coverage for Symproic® effective.
- Zacks
What Makes BioDelivery (BDSI) a New Buy Stock
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- GlobeNewswire
BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development
BioDelivery Sciences International, Inc. (BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced today the appointment of Kevin Ostrander as Senior Vice President of Business Development and member of the Company Executive Leadership Team, effective today January 6. Mr. Ostrander brings nearly thirty years of significant experience executing a multitude of business development strategies, including in-licensing and acquisition of products, establishing joint ventures and strategic partnerships, and creating and running platform collaborations. “I am pleased to welcome Kevin to our rapidly growing Company,” stated Herm Cukier, CEO of BDSI.
- Zacks
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA
Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.
- Barrons.com
Argo Group, Tivity Health, Horizon Global, and Other 13D Filings
13Ds are filed with the Securities and Exchange Commission within 10 days of an entity’s attaining a greater than 5% position in any class of a company’s securities. On Dec. 20, Voce submitted a requisition notice on behalf of shareholders holding more than 10% of Argo’s outstanding stock that requires Argo to hold a special meeting within 60 calendar days from the date of the notice. The meeting is to vote for the removal and replacement of five director’s of Argo’s board with an equal number of Voce nominees submitted to Argo through a separate letter.
- Zacks
Are You Looking for a Top Momentum Pick? Why BioDelivery Sciences International (BDSI) is a Great Choice
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
- GlobeNewswire
BioDelivery Sciences Added to NASDAQ Biotechnology Index
RALEIGH, N.C., Dec. 19, 2019 -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
- Zacks
BioDelivery (BDSI) Up 6% Since Last Earnings Report: Can It Continue?
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Insider Monkey
Did Hedge Funds Drop The Ball On BioDelivery Sciences International, Inc. (BDSI) ?
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]
- Zacks
What Makes BioDelivery Sciences International (BDSI) a Strong Momentum Stock: Buy Now?
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
- Thomson Reuters StreetEvents
Edited Transcript of BDSI earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 BioDelivery Sciences International Inc Earnings Call
- Zacks
Zacks.com featured highlights include: Sciences International, Air Industries, Hallmark Financial Services and Vector
Zacks.com featured highlights include: Sciences International, Air Industries, Hallmark Financial Services and Vector
- Zacks
Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU
The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.
- Zacks
5 Affordable Breakout Stocks for Stunning Returns
Selecting breakout stocks continues to be one of the most popular methods utilized by active investors.
- Zacks
BioDelivery's Belbuca Sales & Symproic Addition Encouraging
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
- GlobeNewswire
BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference
RALEIGH, N.C., Nov. 27, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
- GlobeNewswire
BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors
BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that it has named Vanila M. Singh, M.D., MACM, to its Board of Directors. Dr. Singh is currently a Clinical Associate Professor of Anesthesiology, Pain and Peri-operative Medicine at Stanford University School of Medicine and is a teaching mentor at Walter Reed National Military Medical Center.
- Zacks
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
- Zacks
Protalix Finalizes Accelerated Approval Pathway for PRX-102
Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.
- Zacks
BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View
BioDelivery (BDSI) beats earnings and sales expectations in the third quarter of 2019. The company raises its 2019 revenue guidance.
- Zacks
IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
- Zacks
5 Breakout Stocks for Explosive Returns
Picking breakout stocks is one of the most-favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.
- Zacks
BioDelivery Sciences International (BDSI) Beats Q3 Earnings and Revenue Estimates
BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 5.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
